Online inquiry

IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (CAT#: GTTS-WQ849MR)

This product GTTS-WQ849MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP
5' Cap	Cap 0
Species	Chimeric; Humanized
RefSeq	NM_001024736.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	80381
UniProt ID	Q5ZPR3

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ849MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ7488MR	IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	GC-1008
GTTS-WQ1777MR	IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	ADCT-301(unconjugated)
GTTS-WQ3552MR	IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	BAX069
GTTS-WQ9750MR	IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	JR-141
GTTS-WQ12447MR	IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	NKTR-214
GTTS-WQ6689MR	IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	DNIB0600A
GTTS-WQ1702MR	IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	aDabi-Fab
GTTS-WQ12122MR	IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	MORAb-003

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST